Privi Speciality Chemicals (PRIVISCL) investor relations material

Executive summary

• Q1 FY27 delivered strong revenue growth, with consolidated income reaching INR 681.42 crore, up 20.01% year-over-year, driven by robust demand in both domestic and international markets and a diversified specialty product portfolio.

• Net profit for Q1 FY27 was INR 84.21 crore, up 35.97% year-over-year, demonstrating business resilience despite global headwinds and no operational or supply chain disruptions.

• Expansion projects are progressing as planned, with capacity set to increase from 48,000 to 54,000 metric tons shortly, and further to 66,000 metric tons by September 2027.

• The company maintains a focus on operational efficiency, cost management, and innovation in specialty aroma ingredients, supporting margin resilience despite volatile input costs.

• The Board recommended a final dividend of ₹10 per equity share for FY26, subject to shareholder approval.

Financial highlights

• Consolidated total income for Q1 FY27 was INR 681.42 crore, up 20.01% year-over-year; EBITDA was INR 167.47 crore, up 18.73% year-over-year, with EBITDA margin at 24.58%.

• Net profit stood at INR 84.21 crore, a 35.97% year-over-year rise; PAT margin improved by 145 bps to 12.4%.

• Gross margin declined to 44.2% from 51% in Q1 FY26 due to normalization of raw material costs after a period of low-cost inventory.

• Basic and diluted EPS for Q1 FY27 was ₹21.56, compared to ₹15.85 in Q1 FY26.

• ROE and ROCE for the quarter were 21.7% and 22.72%, respectively.

Outlook and guidance

• Management reiterated guidance of achieving INR 5,000 crore revenue and INR 1,000+ crore EBITDA within 3-4 years, targeting a 20% CAGR with stable EBITDA margins.

• No change in guidance despite minor project delays; capacity expansions are on track for completion by September 2027.

• New specialty products and backward integration initiatives are expected to drive future growth beyond the current roadmap.

• The company is progressing with the amalgamation of Privi Fine Sciences and Privi Biotechnologies, with the scheme filed before the NCLT.